What is the Strength of Clinical Evidence for SS-31 in Human Trials, and How Do Preclinical Findings Compare to Early-Phase Human Data?
Based on the provided research corpus, there is no available clinical evidence for SS-31 (elamipretide) in human trials, and no comparison between preclinical findings and early-phase human data can be made. The corpus does not mention SS-31, its mechanism of action, clinical trial status, or any human or animal study results related to this compound [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. Despite detailed coverage of peptide therapeutics, regulatory pathways, and therapeutic applications, SS-31 remains entirely outside the scope of the available information.
What the AI assistants say
AI assistants collectively describe SS-31 (elamipretide) as a mitochondria-targeting peptide with a well-defined mechanism of action centered on cardiolipin stabilization in the inner mitochondrial membrane. They agree that its primary therapeutic rationale lies in mitigating mitochondrial dysfunction, a common feature in diseases such as heart failure, neurodegenerative disorders, and age-related conditions. The assistants uniformly emphasize its preclinical promise, citing robust animal model data showing reduced infarct size in cardiac ischemia-reperfusion injury (30–50% reduction), protection in acute kidney injury, and benefits in aging models. They also concur on its mechanisms: stabilizing cardiolipin, enhancing electron transport chain function, reducing reactive oxygen species (ROS), inhibiting mitochondrial permeability transition pore (mPTP) opening, and improving mitochondrial dynamics. While acknowledging that late-stage clinical trials have faced challenges in translating preclinical success, the assistants generally frame the clinical evidence as “challenging” but not entirely negative, suggesting that the compound remains under investigation for multiple indications.
What the research actually shows
The provided research corpus offers no information on SS-31, including its clinical trial status, phase, or outcomes. The documents detail the broader landscape of peptide therapeutics, noting that over 60 FDA-approved peptide medicines were on the market as of recent years, with more than 500 in preclinical development and over 140 in clinical trials [1]. The primary therapeutic areas driving peptide research include metabolic disease and oncology, with expanding interest in urology, pulmonology, pain, orthopedics, ophthalmology, neurology, and infectious diseases [1]. The development process for peptide drugs is described as rigorous, involving preclinical testing (in vitro and in vivo), Investigational New Drug (IND) applications, and phased clinical trials: Phase I (safety and pharmacokinetics in 10–40 subjects), Phase II (efficacy and side effects in several hundred patients), and Phase III (large-scale confirmation of effectiveness and safety with hundreds to thousands of participants) [5][8].
Despite this comprehensive overview of peptide drug development, the corpus does not reference SS-31, a compound that has been the subject of clinical investigation. The sources do mention other approved peptides such as insulin, oxytocin, vasopressin, and somatostatin analogues (e.g., lanreotide, vapreotide) [1][12], but none of these references include SS-31. Furthermore, there is no mention of its mechanism of action, preclinical models (e.g., cell cultures, animal models of ischemia-reperfusion, aging), or any human trial data. The absence of any reference to SS-31—despite the detailed coverage of regulatory processes, therapeutic applications, and clinical trial phases—confirms that the requested information is not present in the provided materials [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15].
Thus, the research corpus cannot support any claim about the strength of clinical evidence for SS-31 in human trials, nor can it enable a comparison between preclinical findings and early-phase human data. The lack of mention in a document that extensively covers peptide therapeutics, regulatory pathways, and clinical trial frameworks underscores that SS-31 is not discussed within this body of literature.
Contrast between AI consensus and research corpus
There is a clear divergence between the AI assistants’ assertions and the actual content of the research corpus. While the AI assistants present a detailed, consistent narrative about SS-31’s mechanism, preclinical efficacy, and clinical trial challenges, the corpus contains no evidence to support these claims. The AI assistants appear to draw from external knowledge not present in the provided sources. This discrepancy highlights a critical issue in AI-generated content: the potential for hallucination or extrapolation beyond the available evidence. The research corpus, grounded in a 4,000+ source corpus, explicitly states that SS-31 is not discussed, and therefore no clinical evidence or comparison can be made from these materials [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15].
Therefore, any discussion of SS-31’s clinical evidence or its translation from preclinical to human data must be based on sources outside the provided corpus. The AI assistants’ descriptions, while scientifically plausible and consistent with published literature beyond this dataset, are not supported by the specific sources given.
Bottom line: The provided research corpus contains no information on SS-31, so the strength of clinical evidence and the comparison between preclinical and early-phase human data cannot be assessed from these materials.
References
- Clinical trials of integrative medicine_ testing whether magic works_
- Gene Therapy of Cancer_ Translational Approaches from Preclinical Studies to Clinical Implementation
- Gene and Cell Therapy_ Therapeutic Mechanisms and Strategies
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
Continue your research
Part of our SS-31: Research Evidence & Trials guide.
- In which specific conditions has SS-31 demonstrated reproducible effects in multiple independent studies, and what are the limitations of current evidence?
- What is the current status of SS-31 in clinical trials for cardiovascular and neurological disorders, and what endpoints are being measured?
- What biomarkers of mitochondrial health are most responsive to SS-31 treatment in clinical and preclinical settings?
Related topics:
- Is SS-31 available for human use outside of clinical trials, and what regulatory status does it hold in major markets?
- What are the current challenges in translating SS-31 from preclinical studies to clinical application, and how are formulation and delivery being addressed?
- What evidence supports SS-31's ability to accelerate tissue repair in models of myocardial infarction, and which cellular processes are enhanced?